Green Cross Holdings Corporation

KSE 005250.KS

Green Cross Holdings Corporation Return on Capital Employed (ROCE) for the year ending December 31, 2023: -0.98%

Green Cross Holdings Corporation Return on Capital Employed (ROCE) is -0.98% for the year ending December 31, 2023, a -124.54% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Green Cross Holdings Corporation Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 4.00%, a -26.25% change year over year.
Green Cross Holdings Corporation Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 5.42%, a -16.86% change year over year.
Green Cross Holdings Corporation Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 6.52%, a 294.57% change year over year.
Green Cross Holdings Corporation Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 1.65%, a -34.07% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

KSE: 005250.KS

Green Cross Holdings Corporation

CEO	Mr. Il-Sup Huh Ph.D.
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	107, Ihyeon-ro 30beon-gil
Employees	154
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.

Key trends

Past 5 years